PartnerFacts
Data last updated: Oct 23, 2026, 5:45 PM ETLatest filing: Oct 22, 2026Now: Oct 24, 2026, 9:28 AM ET

Sponsor Check › Person

MG
No photo found yet (own website and image search run after this page is viewed)

Mark Gelfand

Named as an officer, director or promoter on SEC Form D filings · NJ, NY, ND · Jun 7, 2012 → May 13, 2020

3deals (issuers)
$85.4Mreported sold
19investors
12Form D filings
2012–2020years on file

Data last updated Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 24, 2026, 2:25 AM ET · SEC enforcement last checked: covered by the index scan as of Oct 24, 2026, 2:50 AM ET

The short version

Mark Gelfand is listed as an executive officer and director on 12 SEC Form D filings by 3 issuers between Dec 2010 and Jun 2025: Axon Therapies Inc. (New York, NY — other technology — 2016–2019; $75M reported sold to 10 investors), CorVent Medical, Inc. (Fargo, ND — other health care — 2020–2025; $5.42M reported sold to 6 investors) and Coridea NC1, Inc. (New York, NY — biotechnology — 2010–2012; $5M reported sold to 3 investors).

What this means A repeat sponsor — 3 separate companies raised money with this person listed as executive officer and director, over about 15 years. Across those companies the filings report $85.4M sold in total.

Listed alongside Mitchell S. Bloom (7 shared filings), Howard R. Levin (4 shared filings), Paul LaViolette (4 shared filings), Howard R. Levin, M.D. (3 shared filings), Jeremy Nelson (3 shared filings) and 15 others.

What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Mark. Each name links to their own page.

Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CO, CT, DC, DE, FINRA, FL, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, NY, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, WA, WI, WV, WY) — 1 bankruptcy case matching the name listed in Key records below.

What this means 1 record came back. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.

We compared 12 public filings for Mark Gelfand and found 15 differences, 4 worth asking the sponsor about: Bankruptcy case: Mark Gelfand; Amount sold went down between filings; and more below.

What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.

What the community is saying

Community search for Mark Gelfand has not run yet — it is joining a line of 33,647 names; searches run around the clock at the hosts' allowed rate. Searched so far: 638 names.

Community comments are quoted as written by their authors. Sources searched: Bing (site:reddit.com / site:biggerpockets.com) and Reddit's own search, plus DuckDuckGo/Brave/BiggerPockets search when they are answering.

Key records

Five things investors ask first. Items still in human review are counted, not shown.

1. Lawsuits

None found in sources searched — federal courts (CourtListener / RECAP), checked Oct 24, 2026

What was searched

Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30; recall-first rule 10-24) — federal district + bankruptcy courts State courts: not covered (one-tap state court links under Look further). PACER: not searched. · Last checked Oct 24, 2026, 2:25 AM ET.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

2. Regulatory actions

None found in sources searched — SEC enforcement releases (index scan as of Oct 24, 2026, 2:50 AM ET) · state securities regulators: 48 regulators (FINRA, NASAA, 37 states) — crawled Oct 24, 2026, 8:48 AM ET

What was searched

SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — Searched SEC litigation releases and administrative proceedings (1995→ / 2007→) (30,205 records as of Oct 24, 2026, 2:50 AM ET) — nothing matched Mark Gelfand..

State securities regulators: Securities regulators searched (64,910 actions): FINRA (38,350 actions, 1995–2026), NASAA (31 actions, 2000–2026; listing starts 1997), AK Division of Banking and Securities (273 actions, 1971–2025), AL Securities Commission (880 actions, 2001–2026), AR Securities Department (1,305 actions, 1998–2026), AZ Corporation Commission Securities Division (411 actions, 2017–2026), CA DFPI (25 actions, 2007–2024; listing starts 2002 — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), CO Division of Securities (731 actions, 2001–2026; older years from the Internet Archive (snapshot of 2026-05-02)), CT Department of Banking Securities Division (940 actions, 2006–2026; older years from the Internet Archive (snapshot of 2026-04-22)), DC DISB Securities Bureau (25 actions, 2012–2026), DE DOJ Investor Protection Unit (257 actions, 1987–2026), FL Office of Financial Regulation (49 actions, 2018–2026), GA Secretary of State Securities Division (65 actions, 2015–2026; listing starts 2012), HI DCCA Securities Enforcement Branch (26 actions, 2012–2026), ID Department of Finance Securities Bureau (663 actions, 1994–2026), IL Secretary of State Securities Department (4,122 actions, 2003–2023), KS Insurance Department Securities Division (58 actions), KY Department of Financial Institutions (342 actions, 2005–2026), LA Office of Financial Institutions Securities Division (13 actions, 2010–2025; listing starts 2008), MA Secretary of the Commonwealth Securities Division (125 actions, 2012–2025; live site blocks automated access — loaded from the Internet Archive snapshot of 2026-02-04), MD Attorney General Securities Division (1,054 actions, 2004–2026), ME Office of Securities (539 actions, 2000–2026), MI LARA Corporations, Securities & Commercial Licensing Bureau (201 actions), MO Secretary of State Securities Division (919 actions, 1998–2026), MS Secretary of State Securities Division (209 actions, 1995–2026), MT Commissioner of Securities and Insurance (597 actions, 2000–2026), NC Secretary of State Securities Division (265 actions, 2004–2024), ND Securities Department (711 actions, 1990–2026; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2026-01-06), NH Bureau of Securities Regulation (402 actions, 2002–2026), NM Regulation and Licensing Department Securities Division (90 actions, 2010–2025), NV Secretary of State Securities Division (118 actions, 2018–2026), NY Attorney General Investor Protection Bureau (44 actions, 2012–2026), OH Division of Securities (327 actions, 1993–2006), OK Department of Securities (2,531 actions, 1998–2026), OR Division of Financial Regulation (589 actions, 1988–2026), PA Department of Banking and Securities (1,448 actions, 2008–2024; the regulator no longer publishes this list live — loaded from the Internet Archive snapshot of 2024-08-09), RI DBR Securities Division (98 actions, 2005–2025), SC Attorney General Securities Division (540 actions, 2006–2026), SD Division of Insurance – Securities Regulation (106 actions, 2017–2026), TN Department of Commerce and Insurance Securities Division (405 actions, 1992–2026), TX State Securities Board (936 actions, 1999–2026), UT Division of Securities (772 actions, 2000–2026; older years from the Internet Archive (snapshot of 2010-05-27)), VT DFR Securities Division (137 actions, 2010–2026), WA DFI (2,039 actions, 2001–2026), WI DFI Division of Securities (1,072 actions, 1998–2026), WV Securities Commission (State Auditor) (64 actions), WY Secretary of State Compliance Division (6 actions, 2016–2024) — last crawled Oct 24, 2026, 8:48 AM ET. No machine-readable public listing today for IA, IN, MN, NE, NJ, VA (see docs/state-regulators.md).

3. Bankruptcies

1 case: 1 closed (disposition not in docket feed)

Mark Gelfand closed
United States Bankruptcy Court, S.D. Florida. · No. 11-29537 · Filed Jul 14, 2011 · Closed Oct 3, 2014
Role of Mark Gelfand: Debtor · Outcome: Case closed 2014-10-03 (disposition not included in the bulk docket feed — see docket) Docket on CourtListener ↗
same full name (rare in federal dockets); court in FL (not a filing state)
What was searched

Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not covered (one-tap state court links under Look further). PACER: not searched (RECAP only). · Last checked Oct 24, 2026, 2:25 AM ET.

Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.

State courts: not covered (one-tap state court links under Look further). No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.

4. Differences between public sources

Comparisons cover issuers and sponsor groups — see the issuer pages under Deals

15 differences found between the filings for Mark Gelfand — 4 worth asking about (compared 12 filings on Oct 24, 2026)

Worth asking · Jul 14, 2011 – Oct 3, 2014

Bankruptcy case: Mark Gelfand — filed Jul 14, 2011

United States Bankruptcy Court, S.D. Florida. docket "Mark Gelfand" filed Jul 14, 2011, closed Oct 3, 2014. Mark Gelfand is listed as Debtor. Our match estimate: 40%.

What this means A bankruptcy filing was found. Many are old or personal and have nothing to do with the deal — but ask what it was and when it closed.

Sources
Worth asking · Feb 7, 2019

Amount sold went down between filings — Axon Therapies Inc.

The Feb 7, 2019 filing says $74,999,993 sold; the Feb 7, 2019 Form D/A says $7,499,994 sold — $67,499,999 less.

What this means Amounts sold normally only go up as a raise continues. A drop can mean investors were refunded, a figure was corrected, or an earlier number was wrong. Ask the sponsor which it was.

Sources
Note · Feb 7, 2019

Mark Gelfand appears on 1 deal that stopped filing before reaching its target

Axon Therapies Inc. (last filing Feb 7, 2019; $74,999,993 sold of $150,000,000). Each has no filing in more than two years and reported under half its target sold.

What this means An issuer whose last filing is more than two years old and reported under half its target sold. The raise may have closed early or quietly stopped. Ask what happened to each.

Sources
Worth asking · May 13, 2020

Paid seller listed without a CRD number: 0 — CorVent Medical, Inc.

0 is listed as receiving sales compensation on 1 filing (May 13, 2020) with no FINRA CRD number given.

What this means People paid to sell securities normally hold a FINRA registration with a CRD number. Without one we cannot look them up on BrokerCheck. Ask who they are and whether they are registered.

Sources
Worth asking · Dec 11, 2023 – Dec 13, 2024

Form D filed 368 days after the first sale — CorVent Medical, Inc.

The filing says the first sale was Dec 11, 2023. The Form D was filed Dec 13, 2024 — 368 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 353 days past that.

What this means The notice went in months after money was taken in. Late notices are common and carry no penalty by themselves, but it is fair to ask the sponsor why the paperwork lagged.

Sources
Note · Dec 14, 2024 – Dec 30, 2024

Form D filed 16 days after the first sale — CorVent Medical, Inc.

The filing says the first sale was Dec 14, 2024. The Form D was filed Dec 30, 2024 — 16 days later. The rule: a Form D is generally due within 15 days after the first sale, so this one is 1 days past that.

What this means A late notice is common and carries no penalty by itself. It is worth asking the sponsor why the paperwork lagged.

Sources
Note · May 25, 2012 – Jun 27, 2025

4 offerings have no amendment in the last 12 months and may still be open

No amendment in the last 12 months on an offering that may still be open — CorVent Medical, Inc. (latest filing Jun 27, 2025) · No amendment in the last 12 months on an offering that may still be open — Axon Therapies Inc. (latest filing Feb 7, 2019) · No amendment in the last 12 months on an offering that may still be open — Axon Therapies Inc. (latest filing Jun 28, 2017) · No amendment in the last 12 months on an offering that may still be open — Coridea NC1, Inc. (latest filing Jun 7, 2012)

What this means SEC rules expect a yearly amendment while an offering is still going. Ask the sponsor which of these raises have closed.

Sources
Note · May 13, 2020 – Dec 13, 2024

Mark Gelfand's role changed at CorVent Medical, Inc.: executive officer, director → director

The May 13, 2020 filing lists Mark Gelfand as executive officer, director; the Dec 13, 2024 Form D lists director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Sources
Note · Jun 28, 2017 – Feb 7, 2019

Mark Gelfand's role changed at Axon Therapies Inc.: executive officer → executive officer, director

The Jun 28, 2017 filing lists Mark Gelfand as executive officer; the Feb 7, 2019 Form D/A lists executive officer, director.

What this means Roles on Form D are self-reported by the issuer. A change can mean a real change in who runs the company, or just a different box ticked. Ask who makes decisions today.

Sources
Note · Dec 30, 2024 – Jun 27, 2025

Offering amount changed between filings — CorVent Medical, Inc.

The Dec 30, 2024 filing says $3,000,000 offered; the Jun 27, 2025 Form D/A says $6,500,000.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Sources
Note · Feb 7, 2019

Offering amount lowered between filings — Axon Therapies Inc.

The Feb 7, 2019 filing says $150,000,000 offered; the Feb 7, 2019 Form D/A says $15,000,000.

What this means The target raise got smaller. That can mean the plan shrank or the sponsor stopped early. Ask what changed in the deal.

Sources
Note · Dec 17, 2010 – Oct 17, 2011

Offering amount changed between filings — Coridea NC1, Inc.

The Dec 17, 2010 filing says $1,500,000 offered; the Oct 17, 2011 Form D/A says $3,000,000.

What this means The target raise changed. Raising the cap is common when a deal grows; ask whether the extra money has the same terms and use.

Sources
Note · May 13, 2020 – Dec 13, 2024

Address moved from New York, NY to Fargo, ND — CorVent Medical, Inc.

The people listed on the May 13, 2020 filing give New York, NY; on the Dec 13, 2024 filing they give Fargo, ND.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Sources
Note · Oct 17, 2011 – Jun 7, 2012

Address moved from Teaneck, NJ to New York, NY — Coridea NC1, Inc.

The people listed on the Oct 17, 2011 filing give Teaneck, NJ; on the Jun 7, 2012 filing they give New York, NY.

What this means Businesses move; this just shows the two places and dates. If you were told one city and the forms say another, ask which is current.

Sources
Note · Dec 17, 2010 – Jun 27, 2025

Mark Gelfand is listed with 3 different address states: NJ, NY, ND

NJ on 2 filings (Dec 17, 2010 to Oct 17, 2011); NY on 7 filings (Jun 7, 2012 to May 13, 2020); ND on 3 filings (Dec 13, 2024 to Jun 27, 2025).

What this means The address on a Form D is usually the company's, not the person's home, so this often just reflects different companies. It can also mean a move. Nothing wrong by itself.

Sources
What is compared

What is compared: every Form D and D/A we hold for this subject, side by side — filing dates vs. first-sale dates (the 15-day rule), amendment timing on open offerings (the yearly-amendment expectation), amounts sold, investor counts, offering amounts and minimums across amendments, industry and size bands, addresses, how each person's name and role is written, paid sellers' CRD numbers, and (for groups) where the member companies were formed and sit. Everything is as filed by the issuer; the SEC does not check it. Differences are common and usually have ordinary explanations — we show both values, the dates, and the source so you can ask. As of Oct 24, 2026.

5. Money to insiders

0 of 8 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.

Offering (latest filing)Sales commissionsFinder's feesTo insidersPaid to sell itSource
Jun 27, 2025 D/A
CorVent Medical, Inc.
File 021-533708
$0$0$0None listed on this filingEDGAR ↗
Dec 13, 2024 D
CorVent Medical, Inc.
File 021-532053
$0$0$0None listed on this filingEDGAR ↗
May 13, 2020 D/A
CorVent Medical, Inc.
File 021-366807
$0$0$0None listed on this filingEDGAR ↗
Feb 7, 2019 D/A
Axon Therapies Inc.
File 021-332379
$0$0$0None listed on this filingEDGAR ↗
Jun 28, 2017 D
Axon Therapies Inc.
File 021-289607
$0$0$0None listed on this filingEDGAR ↗
Apr 19, 2016 D
Axon Therapies Inc.
File 021-261599
$0$0$0None listed on this filingEDGAR ↗
Jun 7, 2012 D
Coridea NC1, Inc.
File 021-179426
$0$0$0None listed on this filingEDGAR ↗
Oct 17, 2011 D/A
Coridea NC1, Inc.
File 021-152096
$0$0$0None listed on this filingEDGAR ↗
How this is counted

Counts come from Form D Items 12–15 on the filings in our index (latest filing per offering; one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.

Counted across every filing this person is listed on (latest filing per offering, per issuer).

Deals 3

Every issuer that named Mark Gelfand on a Form D, newest first. A Form D is the notice a company files after it starts selling a private investment.

Other Health Care

CorVent Medical, Inc.

Fargo, ND · May 13, 2020 → Jun 27, 2025 · 5 filings
  • Jun 27, 2025 · D/A · $3,750,000 sold of $6,500,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 30, 2024 · D · $2,600,000 sold of $3,000,000 · 4 investors · min. No minimum reported · role: Director EDGAR ↗
  • Dec 13, 2024 · D · $5,419,066 sold of $5,419,066 · 6 investors · min. No minimum reported · role: Director EDGAR ↗
  • May 13, 2020 · D/A · $4,500,000 sold of $4,500,000 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • May 13, 2020 · D · $4,500,000 sold of $4,500,000 · 6 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗

Raised $5.42M from 6 investors (83% of the $6.5M target) as of the latest filing. Mark is listed as director, executive officer on 5 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Health Care / 506(b) (4,189 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Other Technology

Axon Therapies Inc.

New York, NY · Apr 19, 2016 → Feb 7, 2019 · 4 filings
  • Feb 7, 2019 · D/A · $7,499,994 sold of $15,000,000 · 10 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Feb 7, 2019 · D · $74,999,993 sold of $150,000,000 · 10 investors · min. No minimum reported · role: Executive Officer, Director EDGAR ↗
  • Jun 28, 2017 · D · $1,299,999 sold of $2,000,000 · 7 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
  • Apr 19, 2016 · D · $2,000,000 sold of $2,000,000 · 1 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

Raised $75M from 10 investors (100% of the $15M target) as of the latest filing. Mark is listed as executive officer, director on 4 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer. "Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years: Other Technology / 506(b) (17,390 filings); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.

Biotechnology

Coridea NC1, Inc.

New York, NY · Dec 17, 2010 → Jun 7, 2012 · 3 filings
  • Jun 7, 2012 · D · $5,000,000 sold of $10,000,000 · 3 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
  • Oct 17, 2011 · D/A · $3,000,000 sold of $3,000,000 · 3 investors · min. No minimum reported · role: Executive Officer EDGAR ↗
  • Dec 17, 2010 · D · $1,000,000 sold of $1,500,000 · 3 investors · min. No minimum reported · role: Executive Officer EDGAR ↗

Raised $5M from 3 investors (50% of the $10M target) as of the latest filing. Mark is listed as executive officer on 3 filings for this deal.

Sources

Every row is a Form D or D/A on which the issuer listed this name as a related person. Amount sold and investors are the maximum reported on any filing for this issuer.

People around Mark 20

Officers, directors, promoters and management entities named on the same filings, as of Oct 23, 2026, 5:45 PM ET.

MB
No photo found yet (own website and image search run after this page is viewed)
Person

Mitchell S. Bloom

Executive Officer · 7 shared filings (2 issuers) · also on 10 other issuers

Mitchell S. Bloom is on 12 issuers in total — a repeat sponsor. Their page lists every one.

PL
No photo found yet (own website and image search run after this page is viewed)
Person

Paul LaViolette

Director · 4 shared filings (1 issuer) · also on 19 other issuers

Paul LaViolette is on 20 issuers in total — a repeat sponsor. Their page lists every one.

HL
No photo found yet (own website and image search run after this page is viewed)
Person

Howard R. Levin

Executive Officer, Director · 4 shared filings (1 issuer) · also on 1 other issuer

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

NE
No photo found yet (own website and image search run after this page is viewed)
Person

Neil A. Exter

Director · 3 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

JW
No photo found yet (own website and image search run after this page is viewed)
Person

Jonathan Wyler

Director · 3 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

HD
No photo found yet (own website and image search run after this page is viewed)
Person

Howard R. Levin, M.D.

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

JM
No photo found yet (own website and image search run after this page is viewed)
Person

John O'Mahony

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

JB
No photo found yet (own website and image search run after this page is viewed)
Person

John A. Ballantyne

Director · 3 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

RS
No photo found yet (own website and image search run after this page is viewed)
Person

Randy Schneider

Director · 3 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

RW
No photo found yet (own website and image search run after this page is viewed)
Person

Richard S. Walsh

Executive Officer, Director · 3 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

JC
No photo found yet (own website and image search run after this page is viewed)
Person

John O'Connor

Director · 3 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

JN
No photo found yet (own website and image search run after this page is viewed)
Person

Jeremy Nelson

Executive Officer · 3 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

AE
No photo found yet (own website and image search run after this page is viewed)
Person

Andrew ElBardissi

Director · 2 shared filings (1 issuer) · also on 11 other issuers

Andrew ElBardissi is on 12 issuers in total — a repeat sponsor. Their page lists every one.

IE
No photo found yet (own website and image search run after this page is viewed)
Person

Imran Eba

Director · 2 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

RF
No photo found yet (own website and image search run after this page is viewed)
Person

Rob Faulkner

Director · 2 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

LG
No photo found yet (own website and image search run after this page is viewed)
Person

Lukas Geunther

Director · 2 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

MT
No photo found yet (own website and image search run after this page is viewed)
Person

Mark Tibbles

Director · 2 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

TM
No photo found yet (own website and image search run after this page is viewed)
Person

Travis Murphy

Executive Officer · 2 shared filings (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

SH
No photo found yet (own website and image search run after this page is viewed)
Person

Steven Hochberg

Director · 2 shared filings (1 issuer) · also on 11 other issuers

Steven Hochberg is on 12 issuers in total — a repeat sponsor. Their page lists every one.

MT
No photo found yet (own website and image search run after this page is viewed)
Person

Murphy Travis

Executive Officer · 1 shared filing (1 issuer)

Listed on the same filings as Mark Gelfand. Their page shows their other deals.

The team behind the deals

Same business address

1 other issuer file from the same address

A shared address can mean the same team, a shared office building or a registered agent. It is a lead, not a conclusion.

Registrations and other filings

Business registration (state registry / Secretary of State)

Individuals are not matched to business registrations — registries list companies, and a name alone is not enough to tie a person to one. Officers and managers appear by name inside each matched company's record on the issuer pages. Registries searched: AL (Alabama Secretary of State — Business Entity Records (arc-sos.state.al.us), searched by issuer name, data as of Oct 24, 2026); CO (Colorado Secretary of State — Business Entities in Colorado (data.colorado.gov), data as of Oct 23, 2026); CT (Connecticut Secretary of the State — Business Registry (data.ct.gov), data as of Oct 24, 2026); FL (Florida Department of State, Division of Corporations — quarterly corporate data file (Sunbiz), data as of Oct 7, 2026); NY (New York Department of State — Corporations and Other Entities (data.ny.gov: All Filings + Active Corporations), data as of Oct 20, 2026); OR (Oregon Secretary of State — Active Businesses, All (data.oregon.gov), data as of Oct 20, 2026); PA (Pennsylvania Department of State — Registered Businesses, Current (data.pa.gov), data as of Oct 6, 2026); TX (Texas Comptroller — Active Franchise Taxpayers incl. Secretary of State file data (data.texas.gov), data as of Oct 24, 2026). Registries of other states have not been searched: many publish no bulk file and require a CAPTCHA or bot challenge on their search page, which we do not bypass (Delaware, for example, offers no public bulk file).

Adviser registration (Form ADV)

None of the 3 issuers this person is listed on appears in Form ADV (searched 24,962 advisers as of Oct 2, 2026). A person is never an adviser firm; Form ADV is checked for the issuers and the management companies they are listed with.

Other offering types (Regulation A and Regulation Crowdfunding)

Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.

Property records none — individuals are not matched

Property records are matched to companies only, never to individuals, so none are matched to Mark Gelfand by design. Searched property records in Hillsborough County FL (Clerk recorded-document index Oct 14, 2026 to Oct 15, 2026 + FL DOR 2026 ownership roll), Miami-Dade County FL (FL DOR 2026 ownership roll), Harris County TX (HCAD 2026 ownership roll), Dallas County TX (DCAD 2026 ownership roll), New York City ACRIS documents and PLUTO ownership rows already retrieved for other issuers, Cook County IL sale and ownership rows already retrieved for other issuers (814,874 records as of Oct 23, 2026, 8:59 PM ET) for the 3 issuers this person is listed on — nothing matched.

Public profiles and social

Websites and social links of the issuers Mark Gelfand is listed on: none on file. No website or social profile named in CorVent Medical, Inc.'s SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #66,855 of 374,652 in line (1,386 issuers searched so far). One-tap searches: Look further ↓

Look further

One-tap searches on sites we do not index ourselves, with the name pre-filled (Fargo, ND). Each opens in a new tab; what you find there is not verified by PartnerFacts.

Change history

No corrections have been requested for this page.

Every fact links to its public-record source. Plain-English notes next to a fact are our reading of that fact, not a rating. Request a correction · Facts policy

Request a correction

Free. Logged with status: received → under review → fixed / confirmed with source.

Add a response

If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.

Monitor this person

Members get an email when Mark Gelfand appears on a new Form D, or when a court case or SEC action is matched to them. See plans →